Gilead's Low-Dose, High-Impact HIV Drug Heads To The FDA


Posted on: Wed 08-04-2015

 
A next-generation HIV drug from Gilead Sciences Inc., which could be more effective and have fewer side effects with a lower dosage, will go to federal regulators for a decision on whether it should be approved.
 
The drug — a combination of Gilead's emtricitabine and tenofovir alafenamide, or TAF — is the second so-called F/TAF drug submitted by the Foster City-based company (NASDAQ: GILD) to the Food and Drug Administration. 
 
In November, it filed for approval of a once-daily, single-tablet regiment containing elvitegravir, cobicistat, emtricitabine and TAF, and a decision on that drug is expected by Nov. 5.
 
. Gilead's F/TAF could unleash a fresh round of HIV drug combos, says Chief Scientific Officer Norbert Bischofberger.
 
This latest new drug application, or NDA, filing seeks approval of two doses of F/TAF for adults and children age 12 and older in combination with other HIV antiretroviral drugs. 
 
The filing is backed by a late-stage trial that indicated that F/TAF could fight off the AIDS virus at a dose less than one-tenth that of Gilead's Viread, which features an earlier version of tenofovir at 300 milligrams.
 
The study, with HIV patients who hadn't received antiretroviral drugs previously, pitted F/TAF against Stribild, which includes that earlier version of tenofovir, and found that F/TAF was at least equal in efficacy to Stribild and had fewer kidney and bone side effects than Stribild.
 
Other trials tested F/TAF in adult HIV patients who switched drug regimens, treatment-naive adolescents and adults with mild-to-moderate kidney impairment.
 
The earlier version of tenofovir also is used in Gilead's other HIV-fighting combination drugs — Truvada, Atripla, Complera and Stribild — so F/TAF could serve as the centerpiece for a whole new set of drug combos.
 
By Ron Leuty
San Francisco Business Times